| cyclosporin A microemulsion / Generic mfg. |
| Not yet recruiting | 4 | 28 | | | Heath Department of Western Australia, Novartis Pharmaceutical Company Pty Ltd, Novartis Pharmaceutical Company Pty Ltd | Cardiovascular risk | | | | |
2005-004607-11: Prospective, randomized, long-term study compairing a Neoral (C-0h monitoring)-based steroid-free to an everolimus-myfortic based, calcineurin-inhibitor-free immunosuppressive treatment on graft function and on the long term impact on cardiovascular risk factors after "de novo" kidney transplantation. |
|
|
| Ongoing | 4 | 120 | Europe | Myfortic, certican, sodium mycophenolate, Neoral, Capsule*, Myfortic 180 mg, Certican 0.25 mg, Myfortic 360 mg, Certican 0.50 mg, Certican 0.75 mg, Neoral 10 mg, Neoral 25 mg, Neoral 50 mg, Neoral 100 mg | Hopital Erasme | “De novo†renal transplantation | | | | |
2005-004469-40: Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to ACE-inhibitors alone in the treatment of de novo nephrotic syndrome due to idiopathic membranous glomerulopathy |
|
|
| Ongoing | 4 | 50 | Europe | Neoral, zestril, Capsule*, Tablet, Neoral, zestril | Hopital Erasme | Membranous Nephropathy | | | | |
2005-004460-22: Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to corticosteroids with ACE-inhibitors in the treatment of de novo nephrotic syndrome due to focal segmental glomerulosclerosis. |
|
|
| Ongoing | 4 | 50 | Europe | Neoral, Medrol, zestril, Capsule*, Tablet, Neoral, Medrol, zestril | Hopital Erasme | focal and segmental glomerulosclerosis | | | | |
2008-000252-28: A Multi-Centre Prospective Controlled Trial Comparing Calcineurin Inhibitor Monotherapy With Sirolimus Monotherapy in Hepatitis C Infected Patients with Hepatic Fibrosis Following Liver Transplantation |
|
|
| Ongoing | 4 | 120 | Europe | Neoral, Coated tablet, Capsule, hard, Capsule, soft, Rapamune, Prograf, Neoral | Cambridge University Hospitals NHS Foundation Trust | Patients who have undergone liver transplantation and are infected with Hepatitis C virus. | | | | |
ChiCTR-TNC-11001512: Clinical Study of strictly selected patients with myelodysplastic syndrome (MDS) undergoing immunosuppressive therapy (IST) |
|
|
| Completed | 4 | 100 | | One part patients received antithymocyte globulin (ATG) (Fresenius Kabi Pharmaceutical Co., Ltd. Germany.) for 4 days at a dose of 4 mg/kg/day followed by cyclosporine A (Novartis Pharma Schweiz AG) (3~5 mg/kg/day). The remaining patients received cyclosporine treatment only. | Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, SHDC12010202 | low and intermediary risk MDS | | | | |
| Ongoing | 4 | 100 | Europe | INFLIXIMAB, ETANERCEPT, METHOTREXATE SODIUM TABLETS, CICLOSPORIN A CAPSULES, HYDROXYCARBAMIDE, ACITRETIN, CALCIPOTRIOL, HYDROMOL, SHORT CONTACT DITHRANOL IN HYDROMOL, DITHRANOL IN LASSAR'S PASTE, STRONG COAL TAR SOLUTION IN HYDROMOL, PUVASORALEN-8, Powder for injection*, Powder and solvent for solution for injection, Tablet, Capsule*, Cream, Ointment, REMICADE, ENBREL, METHOTREXATE, NEORAL, HYDREA, NEOTIGASON, DOVONEX CREAM, DOVONEX OINTMENT, HYDROMOL OINTMENT, METHOXSALEN | The Newcastle upon Tyne Hospitals NHS Trust | Psoriasis | | | | |
ChiCTR-TRC-14004216: Clinical trial about Cyclosporin A in the prevention and treatment of recurrent spontaneous abortion |
|
|
| Completed | 4 | 60 | | oral Cyclosporin A 50-75mg t.i.d.(q8h) ×20-30days ;oral Dydrogesterone 10mg t.i.d.(q8h) ×20-30days ;oral Cyclosporin A 50-75mg and Dydrogesterone 10mg t.i.d.(q8h) ×20-30days | The Obstetrics & Gynecology Hospital, Fudan University; The Obstetrics & Gynecology Hospital, Fudan University, Hospital funding | recurrent spontaneous abortion | | | | |
2004-004488-31: Does cyclosporine A reduce the insulin secretion from the pancreas? |
|
|
| Ongoing | 4 | 16 | Europe | Sandimmun Neoral, Sandimmun Neoral, Sandimmun Neoral | Rikshospitalet University Hospital, University of Oslo | Kidney failure / dialysis patients / transplantation | | | | |
2005-004299-19: New Possibilities of TDM of Cyclosporine A and its metabolites after kidney transplantation |
|
|
| Ongoing | 4 | 375 | Europe | not fixed in the protocol | University Hospital Ostrava | patient on standart immunusupresive therapy with cyclosporine A after renal transplantation | | | | |
2005-002266-10: Estudio para comparar la evolución de la hepatitis C con ciclosporina C2 frente a tacrolimus en receptores de trasplante hepático de novo virus C positivos.Study to compare hepatitis C evolution with ciclosporin C2 versus tacrolimus with patients virus C positive who have received a liver transplantation de novo. |
|
|
| Ongoing | 4 | 246 | Europe | Sandimmun Neoral, Prograf, FK506, Sandimmun Neoral, Prograf, Sandimmun Neoral, Prograf | Dr. Evaristo Varo Pérez | Trasplante hepático | | | | |
2004-004947-23: Efficacité de la rapamycine dans la prévention secondaire des cancers cutanés chez les transplantés rénaux. Etude ouverte randomisée Rapamycine vs anticalcineurines |
|
|
| Ongoing | 4 | 25 | Europe | Neoral, Rapamune, neoral, neoral 50MG, Rapamune 1 mg, Neoral 100mg, Rapamune 2 mg, neoral 50MG, Rapamune 1 mg, Neoral 100mg, Rapamune 2 mg | UF de méthodologie en recherche clinique, Hospices Civils de Lyon | To evaluate the impact of two imnosupressive regimens on the incidence of skin cancers among patients who has a first spinocellular skin cancer after renal transplantation | | | | |
2005-004509-27: Intérêt de la rapamicine (Rapamune(R)) pour la prévention secondaire des cancers cutanés chez les transplantés rénaux ayant présentant plus d\'un Carcinome Spinocellaire. |
|
|
| Ongoing | 4 | 25 | Europe | Neoral, Rapamune, neoral, Neoral 50 mg, rapamune 1mg, Neoral 100 mg, rapamune 2 mg, Neoral 50 mg, rapamune 1mg, Neoral 100 mg, rapamune 2 mg | Cliniques Hopitaux Universitaires NANTES, Hospices Civils de Lyon | To evaluate the impact of two immunosuppressive regimens on the incidence of skin cancers among patients who have had previously a first spinocellulaire skin cancer after transplantation | | | | |
2006-004709-24: Mycophenolate sodium (Myfortic®) in the Treatment of Uveitis: a Pilot Study. |
|
|
| Ongoing | 4 | 24 | Europe | Myfortic, Neoral, Prednison, Neoral, Neoral | ErasmusMC | Uveitis | | | | |
2007-000789-19: Withdrawal of Calcineurin Inhibitors (CNIs) during administration of Mycophenolate Mofetil (MMF) in liver transplant patients suffering adverse effects from CNIs: Study of the reduction in rejection risk by therapeutic drug monitoring of Mycophenolate Mofetil |
|
|
| Ongoing | 4 | 130 | Europe | Cellcept, Neoral-Sandimmun, Prograft, Cellcept, Neoral-Sandimmun, Prograft | CHU de Liège, Domaine Universitaire du Sart Tilman | liver transplant patients suffering adverse effects from treatment with calcineurin inhibitors | | | | |
2006-002786-39: A PROSPECTIVE TRIAL , MONOCENTRIC, RANDOMIZED, TO EVALUATE THE RENAL\'S FUNCTION IN SUBJECTS WITH CARDIAC TRANSPLANTED |
|
|
| Ongoing | 4 | 200 | Europe | CERTICAN*60CPS 0,25MG, SANDIMMUN NEORAL*50CPS 10MG, SANDIMMUN NEORAL*50CPS 25MG, SANDIMMUN NEORAL*50CPS 50MG, SANDIMMUN NEORAL*30CPS 100MG, SANDIMMUN*OS FL 50ML 100MG/ML, CERTICAN*60CPS 0,25MG, SANDIMMUN NEORAL*50CPS 10MG, SANDIMMUN NEORAL*50CPS 25MG, SANDIMMUN NEORAL*50CPS 50MG, SANDIMMUN NEORAL*30CPS 100MG, SANDIMMUN*OS FL 50ML 100MG/ML | AZIENDA OSPEDALIERA \"OSPEDALI RIUNITI DI BERGAMO\" (A.O. DI RILIEVO NAZIONALE) | CARDIAC-TRASPLATED | | | | |
2007-003649-34: RENAL RESCUE IMMUNOSUPPRESSION FOLLOWING HEART TRANSPLANTATION |
|
|
| Ongoing | 4 | 56 | Europe | Mycophenolic acid, Ciclosporin, Tacrolimus, Azathioprine, Mycophenolate mofetil, Myfortic, Neoral, Prograf, Cellcept, Myfortic, Neoral, Prograf, Cellcept | University Hospital of South Manchester NHS Foundation Trust | Renal impairment following heart transplantation | | | | |
2009-014436-38: A prospective, open, randomized, single center study comparing the effects of duo therapy with Everolimus and steroids versus triple treatment of low dose calcineurin inhibitor, low-dose MMF and steroids at least one year after renal transplantation.Effects on renal function, tolerability, chronic allograft damage, cardiovascular parameters and malignancies. |
|
|
| Ongoing | 4 | 130 | Europe | Certican, Neoral, Prograft, Mycofenolaat mofetil, Prednisolon 5 PCH, Certican, Neoral, Prograft, Mycofenolaat mofetil CF 500, Prednisolon 5 PCH, Certican, Neoral, Prograft, Mycofenolaat mofetil CF 500, Prednisolon 5 PCH | UMCG | Renal transplantation. | | | | |
2007-002420-15: Phase II-Studie zur Effizienz der vorzeitigen Reduktion von CSA/MMF bei fallendem linienspezifischen Chimärismus nach allogener Stammzelltransplantation nach Konditionierung mit low-dose TBI/Fludarabin bei älteren Patienten mit hämatologischen Erkrankungen |
|
|
| Ongoing | 4 | 200 | Europe | CellCept, CellCept, Cyclosporin A, CellCept, Cyclosporin A | Universität Leipzig | Effizienz der vorzeitigen Reduktion von CSA/MMF bei fallendem linienspezifischen Chimärismus nach allogener Stammzelltransplantation nach Konditionierung mit low-dose TBI/Fludarabin bei älteren Patienten mit hämatologischen Erkrankungen | | | | |
2005-004372-20: A randomised, prospective,open-label, multi-centre study comparing the efficacy and safety of conversion to Sirolimus in stable renal transplant recipients with a cutaneous squamous cell carcinoma. |
|
|
| Ongoing | 4 | 90 | Europe | Sirolimus, neoral, ciclosporin, Tacrolimus, Mycophenolate Mofetil, azathioprine, 12, | Oxford Radcliffe Hospitals NHS Trust | Cutaneous squamous cell carcinoma after kidney transplantation | | | | |
CTRIPS, ChiCTR-IPR-15005990: Cyclosporine A in the Treatment of Interstitial Pneumonitis associated with Sjogren’s syndrome(): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial |
|
|
| Not yet recruiting | 4 | 240 | | glucocorticoid+CsA ;glucocorticoid+placebo | Peking University People's Hospital; Level of the institution：, Hangzhou China-US East China pharmaceutical Co., Ltd. | Sjogren's syndrome | | | | |
ChiCTR-OPN-17013383: Therapeutic Effect And Plasma Concentration Of Cyclosporin A Combined Acitretin For The Treatment Of Psoriasis |
|
|
| Recruiting | 4 | 120 | | acitretin only ;cyclosporin A combined acitretin | Hospital for Skin Diseases, Chinese Academy of Medical Sciences; Hospital for Skin Diseases, Chinese Academy of Medical Sciences, Nanjing pharmaceutical association - Changzhou Siyao Hospital pharmacy institute research fund | Moderate-To-Severe Psoriasis | | | | |
2020-002123-11: CLINICAL STUDY IN WHICH PATIENTS ARE RANDOMIZED TO RECEIVE HYDROXYCHLOROQUINE VS. CYCLOSPORINE - HYDROXYCHLOROQUINE TO COMPARE THEIR EFFICACY IN THE TREATMENT OF COVID-19 PNEUMONIA. ESTUDIO CLÃNICO EN EL QUE LOS PACIENTES SON ALEATORIZADOS A RECIBIR HIDROXICLOROQUINA VS. CICLOSPORINA-HIDROXICLOROQUINA PARA COMPARAR SU EFICACIA EN EL TRATAMIENTO DE LA NEUMONIA COVID-19. |
|
|
| Ongoing | 4 | 280 | Europe | Capsule, soft, Coated tablet, Sandimmun Neoral 25 mg cápsulas blandas Sandimmun Neoral 50 mg cápsulas blandas Sandimun Neoral 100 mg cápsulas blandas, Dolquine 200 mg comprimidos recubiertos | Tatiana Cobo Ibáñez, Gemma MarÃa Mora Ortega, Gonzalo Serralta San MartÃn, Hospital Universitario Infanta SofÃa | COVID-19 PNEUMONIA NEUMONIA COVID-19, COVID-19 PNEUMONIA NEUMONIA COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR1900021757: A randomized controlled trial for hydroxychloroquine sulfate in the treatment of idiopathic membranous nephropathy |
|
|
| Recruiting | 4 | 220 | | Supportive treatment+Perindopril 8 mg/day ;Supportive treatment+Perindopril 8 mg/day+hydroxychloroquine sulfate (200mg 2/d) ;Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml) ;Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml)+hydroxychloroquine sulfate (200mg 2/d) | Nephrology Division, First Hospital Affiliated to Army Medical University; First Hospital Affiliated to Army Medical University, Training Program for Clinical Research Talents of Army Medical University | Idiopathic Membranous Nephropathy | | | | |
CTP/DMILD, ChiCTR1900025087: Cyclosporine A in the treatment of polymyositis /dermatomyositis associated interstitial pulmonary disease: a prospective, opened, multicenter, randomized, controlled clinical study |
|
|
| Not yet recruiting | 4 | 150 | | CsA+glucocorticoid ;CTX+glucocorticoid | Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital, Guangdong Provincial People's Hospital | Polymyositis/Dermatomyositis associated Interstitial Lung Disease | | | | |
NCT02745717: The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia |
|
|
| Completed | 4 | 60 | RoW | Thymoglobulin, Thymoglobuline, Cord blood, Cyclosporine Oral Product, cyclosporine A | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Tongji Hospital, Tongji University School of Medicine, Zhejiang Provincial Hospital of TCM | Severe Aplastic Anemia | 12/21 | 12/21 | | |
NCT04376528: Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy |
|
|
| Recruiting | 4 | 89 | RoW | Cyclosporin A, Mycophenolate Mofetil | West China Hospital | Hepatitis, Autoimmune, Primary Biliary Cholangitis, Immunosuppression | 12/21 | 12/21 | | |
ChiCTR2000040991: Cyclosporine A combined with eltrombopag in the treatment for primary immune thrombocytopenia: a prospective, multicenter, single-arm, open clinical study |
|
|
| Recruiting | 4 | 28 | | Cyclosporine A combined with eltrombopag | The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, self-raised | primary immune thrombocytopenia | | | | |
NCT04009525: Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study |
|
|
| Recruiting | 4 | 800 | RoW | Busulfan, Bu, Cyclophosphamide, Cy, Fludarabine, Flu, Thymoglobulin, ATG, cyclosporine A, CsA, Mycophenolate mofetil, MMF, Tacrolimus, FK506, Methotrexate, MTX, Basiliximab, Simulect, Ruxolitinib | First Affiliated Hospital of Guangxi Medical University, Peking University People's Hospital, Ruijin Hospital, The 923th Hospital of People's Liberation Army, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou General Hospital, Hainan General Hospital, The Affiliated Hospital Of Guizhou Medical University, The First People's Hospital of Yunnan | Thalassemia Major | 05/22 | 05/23 | | |
ChiCTR1900026551: Multiple-center clinical study of pediatric diffuse alveolar hemorrhage in China |
|
|
| Not yet recruiting | 4 | 580 | | Glucocorticoid combined with hydroxychloroquine ;Glucocorticoid combined with azathioprine ;Glucocorticoid combined with methotrexate ;Glucocorticoid combined with cyclosporine A ;Glucocorticoid alone ;Glucocorticoid or combined with immunosuppressive agents | The First Affiliated Hospital of Guangxi Medical Uniersity; The First Affiliated Hospital of Guangxi Medical Uniersity, Self-funding | Diffuse Alveolar Hemorrhage | | | | |
ChiCTR2000033267: The auxiliary effect of cyclosporine A in the thrombectomy for acute ischemic stroke: a prospective, single-center, randomized, controlled, open-label, blinded end point trial. |
|
|
| Not yet recruiting | 4 | 38 | | Intravenous injection of cyclosporine A before mechanical thrombectomy (Using the cyclosporine A solution of 250mg/5ml, Prepare injection as required 2.0mg/kg, i.e. 0.04ml/kg.) ;Intravenous injection of normal saline before mechanical thrombectomy (Use 0.9% sodium chloride solution and inject as per 0.04ml/kg). | Shanghai Ninth People's Hospital affiliated to Shanghai Jiaotong University School of Medicine; Shanghai Ninth People's Hospital affiliated to Shanghai Jiaotong University School of Medicine, Self financing | Ischemic stroke | | | | |
NCT02144857: Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis |
|
|
| Recruiting | 4 | 200 | Europe | etanercept, Enbrel, ustekinumab, Stelara, cyclosporine, Neoral, Secukinumab, Cosentyx, Apremilast, Otezla | University of Athens | Psoriasis | 09/23 | 12/23 | | |
DermAtOmics, NCT05692843: Optimization of Cyclosporin in Atopic Dermatitis Through Multiomic Predictive Models of Treatment Response |
|
|
| Recruiting | 4 | 100 | Europe | Cyclosporin A, Prospective, Follow-up of Cyclospoin treatment already started, Ambispective | Instituto de Investigación Hospital Universitario La Paz | Atopic Dermatitis | 11/23 | 07/24 | | |
ChiCTR2100046724: Cyclosporine A in the treatment of unexplained recurrent abortion: a prospective, randomized, double-blind, superior efficacy, placebo-controlled, single-center trial |
|
|
| Not yet recruiting | 4 | 132 | | Take cyclosporine oral solution ;Take placebo | Taizhou People's Hospital; Taizhou People's Hospital, Research Funding for Postgraduates | Recurrent abortion of unknown cause | | | | |
NCT04239859: Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis |
|
|
| Not yet recruiting | 4 | 40 | RoW | secukinumab, Methotrexate, Cyclosporin A, Acitretin | Singapore General Hospital, Translational Immunology Institute | Plaque Psoriasis | 12/27 | 12/27 | | |
NCT04537689: Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis |
|
|
| Recruiting | 4 | 40 | RoW | Ixekizumab, Methotrexate, Cyclosporin A, Acitretin | Singapore General Hospital, Translational Immunology Institute | Plaque Psoriasis | 12/27 | 12/27 | | |
ChiCTR2200057673: The efficacy and safety of cyclosporine in improving pregnancy outcome of patients with repeated embryo implantation failure：An open, randomized, controlled study |
|
|
| Recruiting | 4 | 172 | | Freezing embryo transfer (FET) ;Freezing embryo transfer (FET)+cyclosporin A 50mg bid | Chongqing Health Center For Women And Children; Chongqing Health Center For Women And Children, Hangzhou ZhongMei Huadong Pharmaceutical Co., Ltd. | repeated embryo implantation failure（RIF） | | | | |
2009-018174-54: MERIDIAN: A 12-month prospective, open-label, randomized, multicenter,parallel-group study to evaluate the efficacy, safety andtolerability of a Myfortic®-based regimen in the conversion from aCNI to everolimus in de novo transplant recipients of ExpandedCriteria of Donor kidneys |
|
|
| | 3/4 | 35 | Europe | Myfortic, Certican, Sandimmun Neoral, Simulect, ERL080, Myfortic, Certican, Sandimmun Neoral, Simulect, Myfortic, Certican, Sandimmun Neoral, Simulect | Novartis Pharma Services AG, Novartis Farmacéutica, S.A., Novartis Services AG | de novo transplant recipients of Expanded Criteria Donor (ECD) kidneys | | 07/10 | | |
